Neoplasms

Symptoms and General Pathology

All Conditions

Neoplasm Metastasis

Neoplastic Processes

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Oxaliplatin

Leucovorin

Fluorouracil

Apatinib

Protein Kinase Inhibitors

Enzyme Inhibitors

Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)

Systemic Chemotherapy

Sintilimab

This study were designed to verify the better method of survival for metastatic ICC. Since the traditional method for metastatic ICC was GEMOX(first-line treatment from NCCN guideline), our previous study found similar results from FOLFOX (second-line treatment from NCCN guideline) compared with GEMOX.

Our current study were conducted for further investigation to verify the better method for metastatic ICC.

ICC(Intrahepatic CholangioCarcinoma) patients with metastasis has a short survival time and poor prognosis after diagnosis. Treatment methods was few and far from satisfaction. The treatment recommended from NCCN guideline was GEMOX(Systemic Chemotheray) and clinical trials. Our previous study has demonstrate FOLFOX (Systemic Chemotheray based on Oxaliplatin#5- fluorouracil) has a similar survival and tumor response compared with GEMOX. Further study was needed to intensive confirmation of the result. We designed this study to demonstrate the hypothesis. Metastasis ICCs were recruited and screened by our criteria. All patients were treated with FOLFOX (Systemic Chemotheray based on Oxaliplatin#5-fluorouracil ), apatinib (one of tyrosine kinase inhibitors) plus sintilimab (one of PD-1 antibody).

Our study were designed to verify the better method of survival for metastatic ICC.

Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

Systemic Chemotherapy Based on Oxaliplatin and 5-fluorouracil, Apatinib Plus Sintilimab for Metastasis ICC: a Single Arm Prospective Study

Postoperative adverse events were graded based on CTCAE v4.03

Sun Yat-sen University

Proffessor

Lenvatinib

Ming Shi, MD

This study were designed to verify the better method of survival for ICC with distant metastasis. Since the traditional method for ICC with distant metastasis. was GEMOX(first-line treatment from NCCN guideline), our previous study found similar results from FOLFOX (second-line treatment from NCCN guideline) compared with GEMOX.

Our current study were conducted for further investigation to verify the better method for with distant metastasis.

ICC (Intrahepatic CholangioCarcinoma) patients with metastasis has a short survival time and poor prognosis after diagnosis. Treatment methods was few and far from satisfaction. The treatment recommended from NCCN guideline was GEMOX (Systemic Chemotheray) and clinical trials. Our previous study has demonstrate FOLFOX (Systemic Chemotheray based on Oxaliplatin#5- fluorouracil) has a similar survival and tumor response compared with GEMOX. Further study was needed to intensive confirmation of the result. We designed this study to demonstrate the hypothesis. Metastasis ICCs were recruited and screened by our criteria. All patients were treated with FOLFOX (Systemic Chemotheray based on Oxaliplatin#5-fluorouracil ), lenvatinib (one of tyrosine kinase inhibitors) plus sintilimab (one of PD-1 antibody).

Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis

Systemic Chemotherapy With Oxaliplatin and 5-fluorouracil, Lenvatinib Plus Sintilimab for With Distant Metastasis: a Single Arm Prospective Study

complete response and partial response per RECIST

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC	NCT04682249	ICC	Systemic Chemot... Sintilimab Apatinib	18 Years - 75 Years	Sun Yat-sen University
Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC	NCT04682249	ICC	Systemic Chemot... Sintilimab Apatinib	18 Years - 75 Years	Sun Yat-sen University
Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis	NCT04769908	ICC	Systemic Chemot... Lenvatinib Sintilimab	18 Years - 75 Years	Sun Yat-sen University

Spots Global Cancer Trial Database for systemic chemotheray